Anna E Bortnick1,2,3, Sanyog G Shitole4, Hayder Hashim5, Pankaj Khullar6, Michael Park7, Michael Weinreich1, Stephen Seibert8, Judah Rauch1,3, Giora Weisz9, Jorge R Kizer4,10. 1. Department of Medicine, Division of Cardiology. 2. Department of Medicine, Division of Geriatrics, Montefiore Medical Center. 3. Albert Einstein College of Medicine, Bronx, New York. 4. Department of Medicine, Cardiology Section, San Francisco Veterans Affairs Health Care System, and Department of Medicine, University of California San Francisco, San Francisco, California. 5. Division of Cardiology, Department of Medicine, MedStar Washington Hospital Center and Georgetown University, Washington DC. 6. Sorin Medical, P.C., Brooklyn. 7. Division of Cardiovascular Medicine, Department of Medicine, University at Buffalo, Buffalo, New York. 8. Department of Anesthesiology, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio. 9. Department of Medicine, Division of Cardiology, New York Presbyterian Hospital, New York. 10. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Abstract
BACKGROUND: Higher residual anatomic disease was associated with increased mortality in a recent randomized controlled trial of revascularization after ST-elevation myocardial infarction (STEMI). Less is known about the impact of residual disease post-STEMI in race-ethnic minorities. METHODS: Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX)- II (SS-II) score is an established scoring method for anatomic disease and prevalent co-morbidities to describe patient complexity. We evaluated residual (r) SS-II in 165 patients from a single center urban US registry (n = 1208) presenting for primary percutaneous coronary intervention of STEMI and treated for 3-vessel or left main and any combination of 0, 1, 2 or 3-vessel disease. RESULTS: The median age was 62 years (IQR 52-70), 29.1% women, 44.9% Hispanic/Latino and 19.4% non-Hispanic Black. Over median of 4.9 years (IQR 2.9-6.3), higher rSS-II was associated with increased death [hazard ratio 2.46 per SD increment in log rSS-II (~five-fold increment on the original scale) 95% CI 1.51, 3.99], death or all-cause readmission (hazard ratio 1.37 per SD increment in log rSS-II 95% CI, 1.11-1.70) and death or cardiovascular disease readmission (hazard ratio 1.46 per SD increment in log rSS-II 95% CI, 1.14-1.88). rSS-II was higher in older women with more co-morbidities, but not different by race-ethnicity. CONCLUSIONS: In summary, higher rSS-II was associated with long-term outcomes post-STEMI in a prospective urban, minority cohort, suggesting a potential role for risk stratification with this measure in a non-trial setting.
BACKGROUND: Higher residual anatomic disease was associated with increased mortality in a recent randomized controlled trial of revascularization after ST-elevation myocardial infarction (STEMI). Less is known about the impact of residual disease post-STEMI in race-ethnic minorities. METHODS: Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX)- II (SS-II) score is an established scoring method for anatomic disease and prevalent co-morbidities to describe patient complexity. We evaluated residual (r) SS-II in 165 patients from a single center urban US registry (n = 1208) presenting for primary percutaneous coronary intervention of STEMI and treated for 3-vessel or left main and any combination of 0, 1, 2 or 3-vessel disease. RESULTS: The median age was 62 years (IQR 52-70), 29.1% women, 44.9% Hispanic/Latino and 19.4% non-Hispanic Black. Over median of 4.9 years (IQR 2.9-6.3), higher rSS-II was associated with increased death [hazard ratio 2.46 per SD increment in log rSS-II (~five-fold increment on the original scale) 95% CI 1.51, 3.99], death or all-cause readmission (hazard ratio 1.37 per SD increment in log rSS-II 95% CI, 1.11-1.70) and death or cardiovascular disease readmission (hazard ratio 1.46 per SD increment in log rSS-II 95% CI, 1.14-1.88). rSS-II was higher in older women with more co-morbidities, but not different by race-ethnicity. CONCLUSIONS: In summary, higher rSS-II was associated with long-term outcomes post-STEMI in a prospective urban, minority cohort, suggesting a potential role for risk stratification with this measure in a non-trial setting.
Authors: Pedro A Villablanca; David F Briceno; Daniele Massera; Ota Hlinomaz; Marissa Lombardo; Anna E Bortnick; Mark A Menegus; Robert T Pyo; Mario J Garcia; Farouk Mookadam; Harish Ramakrishna; Jose Wiley; Michela Faggioni; George D Dangas Journal: Int J Cardiol Date: 2016-06-25 Impact factor: 4.164
Authors: Sanyog G Shitole; Noel Kayo; Vankeepuram Srinivas; Venkatesh Alapati; Charles Nordin; William Southern; Panagiota Christia; Robert T Faillace; James Scheuer; Jorge R Kizer Journal: Am J Cardiol Date: 2016-01-28 Impact factor: 2.778
Authors: Scot Garg; Giovanna Sarno; Patrick W Serruys; Alfredo E Rodriguez; Leonardo Bolognese; Maurizio Anselmi; Nicoletta De Cesare; Salvatore Colangelo; Raul Moreno; Stefania Gambetti; Monia Monti; Laura Bristot; Marco Bressers; Hector M Garcia-Garcia; Giovanni Parrinello; Gianluca Campo; Marco Valgimigli Journal: JACC Cardiovasc Interv Date: 2011-01 Impact factor: 11.195
Authors: Anna E Bortnick; Muhammad Shahid; Sanyog G Shitole; Michael Park; Anna Broder; Carlos J Rodriguez; James Scheuer; Robert Faillace; Jorge R Kizer Journal: Clin Cardiol Date: 2020-07-28 Impact factor: 2.882
Authors: Slayman Obeid; Antonio H Frangieh; Lorenz Räber; Nooraldaem Yousif; Thomas Gilhofer; Kyohei Yamaji; Milosz Jaguszewski; Soheila Aghlmandi; James Adams; Yannik Bockhorn; Christian Templin; Barbara E Stähli; Peter Jüni; Nicolas Rodondi; François Mach; Marco Roffi; Stephan Windecker; Willibald Maier; Fabian Nietlispach; Christian M Matter; Roland Klingenberg; Thomas F Lüscher Journal: Cardiol Res Pract Date: 2018-09-25 Impact factor: 1.866